# Copper Peptide Serum Research and GHK-Cu Delivery Science > Copper peptide serum research for GHK-Cu: dermal copper depot ~97 ug/cm^2, liposomal and microemulsion delivery, penetration coefficients, and the topical-vs-injectable question, cited. How GHK-Cu actually crosses skin and what delivery engineering changes — penetration coefficients, the dermal copper depot, liposomes and microemulsions, read as a formulation ledger. ## What the copper peptide serum research establishes Copper peptide serum research for GHK-Cu starts with a delivery problem and a measured answer. In a human skin penetration study, copper applied as the GHK-Cu tripeptide crossed dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10^-4 cm/h; over 48 hours 136.2 ± 17.5 ug/cm^2 of copper permeated and 97 ± 6.6 ug/cm^2 was retained as a dermal depot [5]. That retained depot is the formulation prize: it means a topical copper peptide can establish prolonged local availability in the dermis rather than washing off the surface. The constraint behind every serum is hydrophilicity. Free GHK has a clogP of -2.24, which limits passive movement through the lipid-rich stratum corneum, and a 2025 review identifies this poor permeability as the central delivery challenge — reporting, for instance, that microneedle pretreatment let about 134 nmol of GHK permeate where intact skin allowed none [11]. So the serum-research record is largely a record of getting the molecule past the barrier, not of whether it works once inside [5][11]. ## Liposomes, microemulsions and delivery engineering Two delivery strategies dominate the recent formulation literature. The first is liposomal encapsulation: roughly 100 nm GHK-Cu liposomes achieved 31.7% (anionic) and 20.0% (cationic) encapsulation efficiency, stayed stable for four weeks at room temperature, and produced 48.9% elastase inhibition in human epidermal cells with no cytotoxicity [7]. Elastase inhibition is an anti-aging readout — elastase degrades elastin — so this links a delivery vehicle to a functional skin effect. The second is the ionic-liquid microemulsion. A 2% GHK-Cu microemulsion delivered to mouse scalp activated Wnt/beta-catenin signaling, upregulated VEGF and HGF, and drove hair follicles into anagen within 6 days versus 9 days for minoxidil, with higher hair density at 28 days and no change in testosterone or estradiol [12]. A 2025 review adds a third lever — physical disruption of the barrier — reporting that microneedle pretreatment let about 134 nmol of GHK permeate where intact skin allowed essentially none, and evaluating palmitoylation (Pal-GHK, clogP 1.14) as a way to make the molecule itself more lipophilic [11]. All of these findings are early-stage — liposome work in epidermal cells, microemulsion work in mice, the enhancement strategies in ex-vivo and model skin — but together they map the engineering directions a serum can take to overcome GHK-Cu's native low bioavailability [7][11][12]. The [copper peptide skin research](/skin-research) covers the downstream matrix effects these vehicles aim to deliver. ## Concentration, stability and what a serum can hold A serum is only as good as the active it keeps intact, and GHK-Cu has specific stability requirements that shape formulation. Topical cosmetic and clinical formulations run roughly 0.05% to 2% (w/w) of the copper peptide [3]. The complex is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio, and its high stability constant (log K around 16.4) is what keeps free, pro-oxidant copper from being released into the product or skin [3]. The blue-violet color of a correctly formulated copper-peptide solution is the expected Cu(II) absorption signature; a shift toward brown or green signals oxidation or precipitation — a built-in visual readout of complex integrity [3]. This is why serum compatibility is a real formulation constraint, not marketing folklore. Strong reducing agents and low-pH actives are the hazard: ascorbic acid below about pH 3.5 reduces the Cu(II) and breaks the complex, and AHAs and BHAs can destabilize it or compete for the copper [3]. A copper-peptide serum and a low-pH vitamin-C serum are therefore chemically at odds — combining them in one layer can degrade both actives at once [3]. The penetration data also argue for patience over potency: because the dermal copper depot builds and persists over roughly 48 hours [5], the relevant variable for a serum is sustained, stable delivery into the dermis rather than a single high surface concentration. ## Topical versus systemic: where the human evidence sits ### Is GHK-Cu topical or injectable more effective for skin repair? Human skin-repair evidence is almost entirely topical. The penetration study quantified a dermal copper depot of about 97 ug/cm^2 retained over 48 hours [5], while free GHK is rapidly cleared systemically — a rat study showed it is metabolized in plasma to the dipeptide histidyl-lysine after intravenous dosing [10]. There is no validated human pharmacokinetic basis for injectable dosing, so the record supports topical formulation, not systemic comparison. That asymmetry is the central fact of the serum-versus-injection question. The topical route has a measured depot, a stability profile and small placebo-controlled dermatology trials behind it [3][5]. The systemic route has rodent pharmacokinetics showing rapid degradation of the free peptide [10] and no completed human pharmacokinetic study — no validated half-life, Cmax or bioavailability for injectable or systemic GHK-Cu [3]. Community injection protocols circulate without a peer-reviewed pharmacokinetic basis, which is why this ledger marks systemic use as a no-human-data line item rather than a comparison it can score. --- A compliance-grade ledger of the GHK-Cu copper-tripeptide literature — every collagen study, skin trial and regulatory status posted as a line item and reconciled to its source, with no clinic behind the statement and nothing here for sale.